Paper Details

  1. Home
  2. Paper Details

Antiviral drugs in chronic hepatitis B: review and meta-analysis.

Author: FerlitoL, GiugnoI, MalaguarneraM, MazzoleniG, PistoneG, RestucciaS

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This study reviewed 20 trials of antiviral drugs for chronic hepatitis B. While adenine arabinoside and its monophosphate were not effective, combination therapy with cortisone showed promising results (45-66% remission). Lamivudine had limited long-term effects due to the development of resistant virus strains. Famciclovir reduced viral levels by 50% and normalized liver enzymes in 30% of patients. Ganciclovir had temporary benefits. While no antiviral drug has replaced interferon as the primary treatment, they offer potential as they target the cause of the disease.
Paper Details　
Original Abstract of the Article :
Many researchers have attempted to identify the drugs capable of acting on the viral replication cycle and maintaining clinical remission in chronic hepatitis B. We evaluated the efficacy of antiviral drugs in chronic hepatitis B, by examination of 20 controlled and non-controlled trials conducted b...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.5414/cpp39004

データ提供：米国国立医学図書館（NLM）

Antiviral Drugs for Chronic Hepatitis B: A Review and Meta-Analysis

Chronic hepatitis B (CHB) is a serious liver infection that can lead to cirrhosis and liver cancer. This research provides a comprehensive review and meta-analysis of antiviral drugs used to treat CHB. The authors analyzed data from 20 controlled and non-controlled trials conducted between 1985 and 1996, evaluating the efficacy of various antiviral agents, including adenine arabinoside, lamivudine, famciclovir, and ganciclovir, in managing CHB.

Antiviral Therapy for Chronic Hepatitis B: A Complex Landscape

This research provides a comprehensive overview of the challenges and complexities associated with antiviral therapy for CHB. The authors highlight the limitations of certain drugs, such as the emergence of drug-resistant HBV variants and the lack of long-lasting effects. They also point to the potential of newer antiviral agents, such as famciclovir, in reducing viral load and improving liver function.

Managing Hepatitis B: A Multifaceted Approach

This research emphasizes the importance of a multidisciplinary approach to managing CHB. It highlights the need for ongoing research and development of new antiviral agents, along with a focus on patient education, lifestyle modifications, and supportive care.

Dr. Camel's Conclusion

This research is a testament to the tireless efforts of scientists in the fight against chronic diseases like CHB. Just as a camel adapts to the ever-changing desert environment, researchers are continually seeking new solutions to combat this challenging infection.

Date :
  1. Date Completed 2001-03-15
  2. Date Revised 2019-06-07
Further Info :

Pubmed ID

11204937

DOI: Digital Object Identifier

10.5414/cpp39004

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.